Interaction between erbb- receptors and heregulin in breast cancer tumor progression and drug resistance

59Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The type 1 growth factor receptor family is increasingly recognized as important in the development and maintenance of breast cancer. The family currently consists of four closely related members: the epidermal growth factor receptor (EGF-R/erbB-1), erbB-2, erbB-3 and erbB-4. Putative ligands which bind directly to or indirectly activate erbB-2/3/4 have been characterized recently. This still growing family of EGF-related growth factors includes gp30, its homolog heregulin (HRG), the rat homolog neu differentiation factor (NDF), glial growth factors (GLIA), ARIA and a 50 kDa factor from COLO 16 cells. The understanding of the function, biology and interactions of these growth factor receptors and their ligands will have far-reaching implications for the prognosis and treatment of breast cancer. This review focuses on advances and future directions for further investigations intended to clarify the mechanism and significance of erbB/ligand interactions in breast cancer. © 1995 Academic Press, Inc.

Cite

CITATION STYLE

APA

Lupu, R., Cardillo, M., Harris, L., Hijazi, M., & Rosenberg, K. (1995). Interaction between erbb- receptors and heregulin in breast cancer tumor progression and drug resistance. Seminars in Cancer Biology, 6(3), 135–145. https://doi.org/10.1006/scbi.1995.0016

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free